Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2025 Filed Feb 24, 2025 22:01 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 806 | $15.29 | $12,323.74 |
DisclosureSEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 4 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,423.855 F3 · balance_after: Includes the addition of 3,795.855 shares of Common Stock acquired from dividend reinvestments not previously reported. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:01 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantCommon Stock | 2,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,434 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:01 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 4,703 | $14.92 | $70,168.76 |
DisclosureSEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,606 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:01 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantCommon Stock | 15,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001859805-25-000002 · wk-form4_1740434496.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,309 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 8,529 | $15.29 | $130,408.41 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,919.157 F3 · balance_after: Includes the addition of 10,490.157 shares of Common Stock acquired from dividend reinvestments not previously reported. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantCommon Stock | 15,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,958 F2 · shares: Represents the shares of Common Stock released to cover the dividend equivalents earned on the PSUs released above. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 46,575 | $14.92 | $694,899.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,535 Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:59 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantCommon Stock | 84,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001859698-25-000004 · wk-form4_1740434367.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,110 F1 · shares: Represents shares of Organon & Co. common stock ("Common Stock") for performance share units ("PSUs") granted to the reporting person on August 09, 2022 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:17 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 6,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,893 Underlying: Common Stock · 6,446 shares Expires 2026-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Organon & Co. common stock. F2 · derivative.exercise_date: On November 7, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two installments on November 7, 2025 and November 7, 2026. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:17 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 2,300 | $15.80 | $36,340.00 |
DisclosureSEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,687.355 Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 21:17 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 6,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000110 · wk-form4_1731100655.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,987.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 1,145 | $20.35 | $23,300.75 |
DisclosureSEC source: 0001821825-24-000095 · wk-form4_1725568236.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,113 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:30 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000095 · wk-form4_1725568236.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,258 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 1,231 | $20.35 | $25,050.85 |
DisclosureSEC source: 0001821825-24-000097 · wk-form4_1725568256.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,333 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC |
DiMarco KathrynCorporate Controller
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000097 · wk-form4_1725568256.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,564 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 3,541 | $20.35 | $72,059.35 |
DisclosureSEC source: 0001821825-24-000098 · wk-form4_1725568268.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,974 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantCommon Stock | 7,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000098 · wk-form4_1725568268.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,515 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 1,645 | $20.35 | $33,475.75 |
DisclosureSEC source: 0001821825-24-000101 · wk-form4_1725568302.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,186 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 16:31 UTC |
Stahler Rachel AChief Information Officer
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000101 · wk-form4_1725568302.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,831 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:32 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 11,927 | $20.35 | $242,714.45 |
DisclosureSEC source: 0001821825-24-000102 · wk-form4_1725568313.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,888 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:32 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantCommon Stock | 21,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000102 · wk-form4_1725568313.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,815 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,231 | $20.35 | $25,050.85 |
DisclosureSEC source: 0001821825-24-000100 · wk-form4_1725568290.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,748 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000100 · wk-form4_1725568290.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,979 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 1,350 | $20.35 | $27,472.50 |
DisclosureSEC source: 0001821825-24-000099 · wk-form4_1725568279.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,659 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:31 UTC |
Falcione AaronChief Human Resources Officer
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000099 · wk-form4_1725568279.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,009 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:30 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 1,564 | $20.35 | $31,827.40 |
DisclosureSEC source: 0001821825-24-000096 · wk-form4_1725568246.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,868 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:30 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000096 · wk-form4_1725568246.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,432 F1 · shares: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Read SEC document |
| August 11, 2024 Filed Aug 12, 2024 21:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 11,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,038 Underlying: Common Stock · 11,519 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon & Co. common stock in three equal installments of 11,519 shares on each of August 11, 2024; August 11, 2025; and August 11, 2026. Read SEC document |
| August 11, 2024 Filed Aug 12, 2024 21:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 3,991 | $20.15 | $80,418.65 |
DisclosureSEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,541.355 Read SEC document |
| August 11, 2024 Filed Aug 12, 2024 21:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 11,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000085 · wk-form4_1723497488.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,532.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC |
Ozuah PhilipDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000071 · wk-form4_1718133372.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.816 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000070 · wk-form4_1718133360.xml · derivative · entry 1 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.813 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:17 UTC |
COX CARRIE SMITHDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000076 · wk-form4_1718133431.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,059.859 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:17 UTC |
Ezekowitz AlanDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000078 · wk-form4_1718133454.xml · derivative · entry 1 Ezekowitz Alan · CIK 0001780209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.814 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:17 UTC |
Gayle Helene DDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000077 · wk-form4_1718133442.xml · derivative · entry 1 Gayle Helene D · CIK 0001487047 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.817 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC |
ESSNER ROBERTDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000074 · wk-form4_1718133408.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.813 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:17 UTC |
Sharp ShaliniDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000079 · wk-form4_1718133465.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,783.9 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:18 UTC |
Patton Cynthia MDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000080 · wk-form4_1718133477.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.814 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 15:16 UTC |
Whiteford Grace PumaDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000072 · wk-form4_1718133383.xml · derivative · entry 1 Whiteford Grace Puma · CIK 0001706213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.813 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:17 UTC |
Leone Deborah RDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000075 · wk-form4_1718133420.xml · derivative · entry 1 Leone Deborah R · CIK 0001859703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.815 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 19:16 UTC |
McGarry Martha EDirector
|
GrantPhantom Stock · Derivative | 9,638.554 | $20.75 | $200,000.00 |
DisclosureSEC source: 0001821825-24-000073 · wk-form4_1718133395.xml · derivative · entry 1 McGarry Martha E · CIK 0001859699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,454.813 Underlying: Common Stock · 9,638.554 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on June 15, 2023, September 14, 2023, December 14, 2023 and March 14, 2024. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,989 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 1,589 | $19.61 | $31,160.29 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,664 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 4,989 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000063 · wk-form4_1715112389.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,248 shares Expires 2023-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 356 | $19.61 | $6,981.16 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,160 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:06 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000061 · wk-form4_1715112359.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · derivative · entry 3 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. F2 · derivative.expiration_date: On each of May 4, 2022, May 4, 2023 and May 4, 2024, one-third of the RSUs vested. Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC |
DiMarco KathrynCorporate Controller
|
Tax withholdingCommon Stock | 428 | $19.61 | $8,393.08 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · nonDerivative · entry 2 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,970 Read SEC document |
| May 04, 2024 Filed May 7, 2024 16:05 UTC |
DiMarco KathrynCorporate Controller
|
Exercise / conversionCommon Stock | 1,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000059 · wk-form4_1715112304.xml · nonDerivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.